Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement HAMILTON, ON and BOSTON and LANSING, Mich., June 10, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and Niowave, Inc., a manufacturer of medical radioisotopes from radium and uranium, today announced that the companies have entered into a collaboration [...]